Results 81 to 90 of about 27,792 (251)

Biological Effects of Selenium‐Containing Ionic Liquids: Cytotoxicity, Mercury Interaction, and Antiproliferative Activity in Glioblastoma Cells

Journal of Applied Toxicology, EarlyView.
ABSTRACT Selenium (Se) is an essential micronutrient that participates in redox regulation and cellular homeostasis. Selenium‐containing ionic liquids (ILsSe) have emerged as hybrid compounds combining the properties of organoselenium molecules with the tunable features of ionic liquids.
Guilherme Schmitt Rieder, Alessandro de Souza Prestes, Fernanda D'Avila da Silva, Nilda de Vargas Barbosa, Alix Y. Bastidas Ángel, Mariana F. Soares, Carolina Martins Fernandes, Maria Anttônia Oliveira Petersen, Manuela Moura Silva, Juliete Nathali Scholl, Fabrício Figueiró, Pablo Andrei Nogara, Laura Orian, Eduardo E. Alberto, Michael Ascnher, Diogo Onofre Gomes de Souza, Debora Guerini de Souza, João Batista Teixeira da Rocha   +17 more
wiley   +1 more source

Impact of CYP2C19 genetics on pharmacokinetic variability of escitalopram and sertraline : a study based on therapeutic drug monitoring data [PDF]

, 2010
Escitalopram and sertraline are among the most widely used drugs in the treatment of depression in Norway. Both drugs show substantial pharmacokinetic variability.
Rudberg, Ida
core  

Current status and future perspectives of platelet function‐guided precision antiplatelet therapy for patients with cerebral infarction

Neuroprotection, EarlyView.
Antiplatelet agents target the cyclooxygenase‐1 (COX‐1)/thromboxane A2 (TXA2) and adenosine diphosphate (ADP)‐P2Y12 (cytochrome P450 2C19 [CYP2C19]‐metabolized) platelet activation pathways, resulting in either drug resistance or over‐inhibition. The individualized therapeutic window balances ischemic risk (triggered by high on‐treatment platelet ...
Guoliang Zhu, Xiaoling Chen, Xinyi Huang, Quandan Tan, Qing Cao, Yali Yang, Yapeng Lin, Jie Yang   +7 more
wiley   +1 more source

CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors

, 2013
Chonlaphat Sukasem,1 Ramaimon Tunthong,2 Montri Chamnanphon,1 Siwalee Santon,1 Thawinee Jantararoungtong,1 Napatrupron Koomdee,1 Santirhat Prommas,1 Apichaya Puangpetch,1 Prin Vathesatogkit21Division of Pharmacogenetics and Personalized Medicine ...
Tunthong R, Puangpetch A, Koomdee N, Sukasem C, Chamnanphon M, Prommas S, Jantararoungtong T, Vathesatogkit P, Santon S   +8 more
core  

Bioactive Natural Products in Cardiovascular Disease: Focus on Thrombotic Events

Phytotherapy Research, EarlyView.
An overview of the role of natural products (NP) in cardiovascular disease prevention, highlighting key mechanisms of action: including antiplatelet, antithrombotic, anti‐inflammatory, and antioxidant effects. Additionally, it illustrates the integration of diet–drug interactions, nutritional epigenetics, and the role of artificial intelligence in ...
Maria Nektaria Magkoulia, Despoina Pantazi   +1 more
wiley   +1 more source

Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome

Cardiovascular Therapeutics, 2019
Objective. The objective of this study is to explore the relationships of the effects of CYP2C19 and PON1 Q192R polymorphism on the activity of clopidogrel and the risk of high platelet responsiveness (HPR) by thrombelastography in patients with acute ...
Wenxing Peng, Xiujin Shi, Xiaoyu Xu, Yang Lin   +3 more
doaj   +1 more source

Functional characterization of two novel CYP2C19 variants (CYP2C19*18andCYP2C19*19) found in a Japanese population

Xenobiotica, 2007
Cytochrome P450 2C19 (CYP2C19) plays an important role in the metabolism of a wide range of therapeutic drugs and exhibits genetic polymorphism with interindividual differences in metabolic activity. We have previously described two CYP2C19 allelic variants, namely CYP2C19*18 and CYP2C19*19 with Arg329His/Ile331Val and Ser51Gly/Ile331Val substitutions,
N. Hanioka, N. Hanioka, Y. Tsuneto, Y. Saito, T. Sumada, K. Maekawa, K. Saito, J. Sawada, S. Narimatsu   +8 more
openaire   +2 more sources

Pharmacokinetic and Pharmacodynamic Interactions Between Anti‐Asthma Drugs and Medicinal Plants: A Comprehensive Review

Phytotherapy Research, EarlyView.
ABSTRACT Asthma affects 260–300 million people worldwide. About 20%–35% of patients use medicinal plants with their asthma medication, often without telling their clinicians. Disclosure rates are low; up to 42% of asthma outpatients use herbal products, with no records in their charts.
Emine Kocyigit, Aylin Bülbül, Betul Kocaadam‐Bozkurt, Osman Bozkurt, Duygu Ağagündüz, Raffaele Capasso   +5 more
wiley   +1 more source

The Diversity of CYP2C19 Polymorphisms in the Thai Population: Implications for Precision Medicine [PDF]

Vorthunju Nakhonsri,1 Shobana John,2,3 Hathaichanok Panumasmontol,4,5 Manassanan Jantorn,4,5 Pongpipat Chanthot,4,5 Nuntachai Hanpramukkun,6 Supaporn Meelarp,7 Chonlaphat Sukasem,2,3 Sissades Tongsima,1 Sukhontha Hasatsri,4 Abhisit Prawang,8 Thanawat ...
Prawang A, Hasatsri S, Meelarp S, Jinda P, John S, Thaingtamtanha T, Hanpramukkun N, Jantorn M, Tongsima S, Atasilp C, Nakhonsri V, Sukasem C, Chamnanphon M, Satapornpong P, Panumasmontol H, Chanthot P, Vanwong N   +16 more
core  

Comparison of pharmacogenomic guidance in Australian prescribing resources and international pharmacogenomic guidelines

Internal Medicine Journal, EarlyView.
Abstract Background Pharmacogenomic‐guided medication management optimises drug therapy to enhance patient outcomes. Despite clinical utility, implementation in Australia remains limited, partly due to the lack of clear and consistent guidance. Aim This study evaluated the presence and consistency of pharmacogenomic testing indication categories and ...
Ruby Soueid, Jackson L. A. Thomas, Luke B. Hesson, Stephen Hughes, Sophie L. Stocker   +4 more
wiley   +1 more source